The phosphoinositide 3-kinase (PI3K) and RAS oncoproteins are activated in many major tumor types and control linked signaling pathways. An inhibitor of PI3K is now shown to shrink tumors in transgenic mouse cancer models. The drug also blocks RAS-induced lung tumors when combined with an inhibitor of mitogen-activated protein kinase kinase (pages 1351–1356).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation
Cell Death & Differentiation Open Access 29 November 2022
-
Enhanced O-GlcNAc modification induced by the RAS/MAPK/CDK1 pathway is required for SOX2 protein expression and generation of cancer stem cells
Scientific Reports Open Access 21 February 2022
-
An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer
Cell Death Discovery Open Access 17 March 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Downward, J. Nat. Rev. Cancer 3, 11–22 (2003).
Marone, R., Cmiljanovic, V., Giese, B. & Wymann, M.P. Biochim. Biophys. Acta 1784, 159–185 (2008).
Engelman, J.A. et al. Nat. Med. 14, 1351–1356 (2008).
Samuels, Y. et al. Science 304, 554 (2004).
Maira, S.M. et al. Mol. Cancer Ther. 7, 1851–1863 (2008).
Gupta, S. et al. Cell 129, 957–968 (2007).
Lim, K.H. & Counter, C.M. Cancer Cell 8, 381–392 (2005).
Davies, B.R. et al. Mol. Cancer Ther. 6, 2209–2219 (2007).
Hingorani, S.R. et al. Cancer Cell 4, 437–450 (2003).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Downward, J. Targeting RAS and PI3K in lung cancer. Nat Med 14, 1315–1316 (2008). https://doi.org/10.1038/nm1208-1315
Issue Date:
DOI: https://doi.org/10.1038/nm1208-1315
This article is cited by
-
Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation
Cell Death & Differentiation (2023)
-
143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models
Acta Pharmacologica Sinica (2023)
-
Enhanced O-GlcNAc modification induced by the RAS/MAPK/CDK1 pathway is required for SOX2 protein expression and generation of cancer stem cells
Scientific Reports (2022)
-
An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer
Cell Death Discovery (2020)
-
Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer
Pharmaceutical Research (2017)